Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine technology
|
| gptkbp:advantage |
rapid development
no risk of infection |
| gptkbp:application |
infectious diseases
immunotherapy |
| gptkbp:approvedBy |
2020
|
| gptkbp:compatibleWith |
gptkb:virus
live virus |
| gptkbp:deliveredBy |
lipid nanoparticles
|
| gptkbp:developedBy |
gptkb:Drew_Weissman
gptkb:Katalin_Karikó |
| gptkbp:enables |
customized vaccines
rapid response to pandemics |
| gptkbp:firstHumanTrial |
2013
|
| https://www.w3.org/2000/01/rdf-schema#label |
mRNA vaccine technology
|
| gptkbp:inducedBy |
immune response
|
| gptkbp:mechanismOfAction |
delivers messenger RNA encoding antigen
|
| gptkbp:patent |
gptkb:Moderna
gptkb:BioNTech |
| gptkbp:regulates |
gptkb:FDA
gptkb:EMA |
| gptkbp:relatedTo |
DNA vaccine technology
traditional vaccine technology |
| gptkbp:sideEffect |
fatigue
injection site pain mild fever |
| gptkbp:storage |
ultra-cold temperatures
|
| gptkbp:usedBy |
gptkb:Moderna
gptkb:Pfizer-BioNTech |
| gptkbp:usedIn |
gptkb:COVID-19_vaccines
|
| gptkbp:bfsParent |
gptkb:Moderna
|
| gptkbp:bfsLayer |
4
|